The DcpS inhibitor RG3039 improves motor function in SMA mice

Area of Science:

• Neurology
• Genetics
• Pharmacology

Background:

• Spinal muscular atrophy (SMA) results from SMN1 gene mutations and insufficient full-length survival motor neuron (SMN) protein.
• Quinazoline derivatives, like RG3039, are investigated for their potential to increase SMN2 promoter activity and inhibit DcpS.

Purpose of the Study:

• To evaluate the efficacy of RG3039 in severe SMA mouse models.
• To assess RG3039's distribution, DcpS inhibition, and effects on SMN expression and motor neuron function.

Main Methods:

• Administration of RG3039 to severe SMA mice and conditional SMA mice.
• Measurement of DcpS enzyme activity, SMN expression, and small nuclear ribonucleoprotein assembly.
• Assessment of survival, weight, motor function, motor neuron integrity, and neuromuscular junction function.

Main Results:

• RG3039 distributed to the central nervous system and robustly inhibited DcpS.
• Treated SMA mice demonstrated dose-dependent improvements in survival, weight, and motor function.
• Enhanced motor neuron and neuromuscular junction function, along with increased muscle size, were observed.

Conclusions:

• RG3039 shows therapeutic potential for SMA by improving motor neuron and neuromuscular junction function, independent of significant SMN expression increase.
• Systemic delivery of RG3039 may complement SMN-restoring therapies for SMA treatment.